European Journal of Epidemiology

, Volume 29, Issue 4, pp 277–284 | Cite as

The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromsø study

  • Kristine Blix
  • Sigrid K. Brækkan
  • Saskia le Cessie
  • Finn E. Skjeldestad
  • Suzanne C. Cannegieter
  • John-Bjarne Hansen
CHRONIC DISEASES

Abstract

Whether the high incidence of venous thromboembolism (VTE) in the elderly can be attributed to cancer is not well studied. We assessed the impact of cancer on risk of VTE in young, middle-aged and elderly. 26,094 subjects without a history of cancer or VTE were recruited from the Tromsø study. Incident cancer (n = 2,290) and VTE (n = 531) were recorded from baseline (1994–1995) through December 31st, 2009. Cox regression with cancer as time-varying exposure was used to calculate hazard ratios with 95 % confidence intervals (CI). Overt cancer was associated with a fivefold (95 %CI 4.3, 6.7) increased risk of VTE, with an age-dependent gradient from 26-fold (95 %CI 12.1, 56.5) increased in the young, ninefold (95 % CI 6.6, 12.7) increased in the middle-aged, and threefold (95 % CI 2.5, 4.5) increased risk in the elderly. The population attributable risks were 14, 27 and 18 %, respectively. Conclusion: The relative risk of VTE by cancer were higher in young compared to elderly subjects, but the proportion of VTEs in the population due to cancer did not differ much across age groups. Our findings indicate that the increased risk of VTE by advancing age cannot be attributed to higher incidence of cancer in the elderly.

Keywords

Venous thromboembolism Cancer Age groups Cohort study Attributable risk 

References

  1. 1.
    Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–4. doi:10.1111/j.1538-7836.2007.02374.x.PubMedCrossRefGoogle Scholar
  2. 2.
    Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007;5(4):692–9. doi:10.1111/j.1538-7836.2007.02450.x.PubMedCrossRefGoogle Scholar
  3. 3.
    Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(Suppl 1):S2–9. doi:10.1038/sj.bjc.6605599.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–22. doi:10.1001/jama.293.6.715.PubMedCrossRefGoogle Scholar
  5. 5.
    Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117(1):19–25. doi:10.1016/j.amjmed.2004.01.018.PubMedCrossRefGoogle Scholar
  6. 6.
    Braekkan SK, Borch KH, Mathiesen EB, Njolstad I, Wilsgaard T, Hansen JB. Body height and risk of venous thromboembolism: the Tromso study. Am J Epidemiol. 2010;171(10):1109–15. doi:10.1093/aje/kwq066.PubMedCrossRefGoogle Scholar
  7. 7.
    Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P. Cancer and venous thromboembolism. Semin Thromb Hemost. 2006;32(7):694–9. doi:10.1055/s-2006-951297.PubMedCrossRefGoogle Scholar
  8. 8.
    Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004;164(15):1653–61. doi:10.1001/archinte.164.15.1653.PubMedCrossRefGoogle Scholar
  9. 9.
    Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–8. doi:10.1182/blood-2002-01-0108.PubMedCrossRefGoogle Scholar
  10. 10.
    Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine. 1999;78(5):285–91.PubMedCrossRefGoogle Scholar
  11. 11.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–50. doi:10.1056/NEJM200012213432504.PubMedCrossRefGoogle Scholar
  12. 12.
    Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–64. doi:10.1001/.458.PubMedCrossRefGoogle Scholar
  13. 13.
    Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, Hansen JB. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromso study. J Thromb Haemost. 2008;6(11):1851–7. doi:10.1111/j.1538-7836.2008.03102.x.PubMedCrossRefGoogle Scholar
  14. 14.
    Norway S. Statistical yearbook of Norway 2009. 2009.Google Scholar
  15. 15.
    Rosendaal FR, Vanhv A, Doggen CJ. Venous thrombosis in the elderly. J Thromb Haemost. 2007;5(Suppl 1):310–7. doi:10.1111/j.1538-7836.2007.02489.x.PubMedCrossRefGoogle Scholar
  16. 16.
    Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer. 2010;103(7):947–53. doi:10.1038/sj.bjc.6605883.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer—a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404–13. doi:10.1016/j.ejca.2012.10.021.PubMedCrossRefGoogle Scholar
  18. 18.
    Larsen IK, Smastuen M, Johannesen TB, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31. doi:10.1016/j.ejca.2008.10.037.PubMedCrossRefGoogle Scholar
  19. 19.
    Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, Hansen JB. Mean platelet volume is a risk factor for venous thromboembolism: the Tromso Study, Tromso, Norway. J Thromb Haemost. 2010;8(1):157–62. doi:10.1111/j.1538-7836.2009.03498.x.PubMedCrossRefGoogle Scholar
  20. 20.
    Campigotto F, Neuberg D, Zwicker JI. Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res. 2012;129(Suppl 1):S85–7. doi:10.1016/S0049-3848(12)70023-3.PubMedCrossRefGoogle Scholar
  21. 21.
    Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.CrossRefGoogle Scholar
  22. 22.
    Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjonneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol. 2010;63(2):223–8. doi:10.1016/j.jclinepi.2009.03.018.PubMedCrossRefGoogle Scholar
  24. 24.
    Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275. doi:10.1371/journal.pmed.1001275.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353(9159):1167–73.PubMedCrossRefGoogle Scholar
  26. 26.
    Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010;8(10):2105–12. doi:10.1111/j.1538-7836.2010.03986.x.PubMedCrossRefGoogle Scholar
  27. 27.
    Weingarz L, Schwonberg J, Schindewolf M, et al. Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry. Br J Haematol. 2013;163(5):655–65. doi:10.1111/bjh.12575.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Kristine Blix
    • 1
  • Sigrid K. Brækkan
    • 1
    • 2
  • Saskia le Cessie
    • 3
  • Finn E. Skjeldestad
    • 4
  • Suzanne C. Cannegieter
    • 3
  • John-Bjarne Hansen
    • 1
    • 2
  1. 1.Hematological Research Group, Department of Clinical MedicineUniversity of TromsøTromsøNorway
  2. 2.Section for Hematology, Division of Internal MedicineUniversity Hospital of North NorwayTromsøNorway
  3. 3.Department of Clinical EpidemiologyLeiden University Medical CenterLeidenThe Netherlands
  4. 4.Women’s Health and Perinatology Research Group, Department of Clinical MedicineUniversity of TromsøTromsøNorway

Personalised recommendations